The rapid expansion of GLP-1 receptor agonist prescriptions is altering long-term financial modeling for healthcare providers and insurers. Payers are struggling to manage immediate pharmaceutical expenditures against anticipated downstream medical cost reductions.
Insurance Coverage and Manufacturing Scale
Insurers are imposing stricter prior authorization criteria to mitigate short-term budget impacts. Concurrently, pharmaceutical manufacturers are investing billions to scale specialized sterile fill-finish capacity to meet global demand.